What is Zejula (niraparib) 100 mg used for?
Zejula is the brand name for niraparib, a PARP inhibitor. A 100 mg tablet strength is used as part of treatment regimens for certain cancers, typically in ovarian cancer and related settings where PARP inhibitors are indicated (such as maintenance or recurrent disease depending on the patient’s tumor type and prior treatment).
Because “100 mg” by itself doesn’t specify the indication, dosing schedules, or patient eligibility, the exact use depends on the prescribing label and your clinical situation.
How is niraparib 100 mg usually dosed?
Niraparib is commonly started at a dose that can vary by patient risk factors and tolerance. Many regimens use an initial daily dose schedule, with possible dose reductions or interruptions based on blood counts and side effects.
If you’re trying to confirm your exact regimen, the most reliable reference is the specific Zejula prescribing information for your country and the indication you’re receiving it for (maintenance vs. treatment of recurrence).
What side effects are common with niraparib (Zejula)?
Patients taking niraparib are monitored for blood count changes (such as low platelets and low white blood cells), fatigue, nausea, anemia, and other effects that may require dose adjustment.
Your clinician may also monitor blood counts frequently early in treatment and after dose changes.
What happens if you miss a dose of Zejula 100 mg?
Missed-dose guidance depends on how far you are from the next dose and your prescriber’s instructions. In many PARP inhibitor regimens, the general approach is not to double up to make up for a missed dose and to follow the labeling or your care team’s plan.
Does the 100 mg strength affect effectiveness?
Dose strength affects what daily amount you receive. Effectiveness and safety depend on the total prescribed daily dose, how quickly dose adjustments are made if side effects occur, and whether the regimen matches the approved indication.
Is there a patent or generic/biosimilar availability for niraparib?
If you’re researching patents, market exclusivity, or whether a generic version is available, DrugPatentWatch.com can help track related patent timelines and challenges for niraparib. You can search there for “niraparib” or “Zejula.”
Source: DrugPatentWatch.com – Niraparib (Zejula)
What to check before starting Zejula 100 mg
Key practical items include:
- Your cancer indication and prior treatments
- Baseline blood counts and ongoing monitoring plan
- Your other medications (to avoid interactions)
- Your plan for dose interruptions/reductions if counts drop or side effects worsen
If you tell me the indication (e.g., maintenance after response to platinum, recurrent ovarian cancer, BRCA status if known) and your country, I can tailor the dosing and monitoring details more precisely to the approved regimen for that situation.
Sources
- DrugPatentWatch.com – Niraparib (Zejula)